Site search
2891 results for '' found
Alfred_Health_GP_News_-_February_2026.pdf
https://app.prompt.org.au/download/257970?code=5731a413-28ee-4c95-950d-981ae6819361
Ms Anita Hazard
With over 20 years of nursing experience, in which many of these have been specialising in research and clinical trials at The Alfred, Anita is currently serving as the research lead for the structural heart team. Anita is dedicated and passionate about the role and future of clinical trials in…
/about/bio/ms-anita-hazard
How_to_get_to_Area_U_-_549_St_Kilda_Road_-_Map_v3.pdf
Making_the_Move_to_549_St_Kilda_Road_-_Flyer_v4.pdf
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in pa
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in pa
/
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants with Von Willebrand Disease (NCT06754852)
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants with Von Willebrand Disease (NCT06754852)
/
A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy [Bemdaneprocel] for Patients with Parkinsons Disease [PD] (NCT06944522)
A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy [Bemdaneprocel] for Patients with Parkinsons Disease [PD] (NCT06944522)
/
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agent (NCT06896916)
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agent (NCT06896916)
/